Overview

Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
GlaxoSmithKline
Treatments:
Lapatinib
Topotecan